Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.35 |
| ▸ | APP | P05067 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4706997 | 0.91 | SYK (0.35) | TLR7APPCYP2D6CYP2C9PTPN1 | |
| Trifluoroacetic Acid SCHEMBL4707756 | 0.89 | TLR7 (0.37) | TLR7CYP2D6CYP2C9SYKCYP3A4 | |
| Trifluoroacetic Acid SCHEMBL4706549 | 0.88 | SYK (0.36) | TLR7APPSYK | |
| SCHEMBL4706999 | 0.83 | SYK (0.40) | TLR7CYP2D6CYP2C9SYK | |
| Trifluoroacetic Acid SCHEMBL4705990 | 0.83 | PTPN1 (0.46) | NLRP3TLR7APPCYP2D6PTPN1 | |
| Trifluoroacetic Acid SCHEMBL4708029 | 0.83 | MEN1 (0.32) | TLR7DHFR | |
| SCHEMBL4707759 | 0.83 | SYK (0.41) | TLR7CYP2D6CYP2C9SYK | |
| Trifluoroacetic Acid SCHEMBL4707434 | 0.81 | CRHR1 (0.37) | TLR7DHFR | |
| SCHEMBL4706552 | 0.81 | TLR7 (0.33) | TLR7 | |
| Trifluoroacetic Acid SCHEMBL4708699 | 0.80 | TLR7 (0.36) | TLR7APPCYP2D6PTPN1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633754-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-06-11 | — | — | EP | disclosed |
| US-7226915-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20040229890-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN JOSEPH (US) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229890-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | PTPN5, PTPRO, PTPN18 | NLRP3 1979/4885TLR7 3293/4885APP 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.